NCT05855291Completed

PET/MRI in Predicting the Outcome of Neoadjuvant Chemoradiotherapy With Esophagectomy in Esophageal Cancer Patients

Name: Clinical Trial NCT05855291
Creator: Chang Gung Memorial Hospital
Keywords: Esophageal Cancer, PET/MRI, diagnostic test, clinical trial, Taiwan

Investigating the Role of Integrated 18FDG-PET/MRI in Predicting the Treatment Outcome of Neoadjuvant Concurrent Chemoradiotherapy Followed by Esophagectomy for Patients With Esophageal Cancer

Chang Gung Memorial HospitalClinicalTrials.govdiagnostic test

Verified

Study focus

Disease/Condition: Esophageal Cancer
Drug/Device/Intervention: PET/MRI
Study type: Interventional
Intervention type: diagnostic test

Sponsor & location

Primary sponsor: Chang Gung Memorial Hospital
Location: Taoyuan, Taiwan

Timeline & enrollment

Phase: N/A
Start date: Jan 22, 2018
End date: Jul 31, 2021
Enrollment: 43 participants

Primary outcome

Overall survival

Summary

Integrated PET/MRI has the advantage to assess the metabolism, diffusion, and perfusion parameters of the tumor simultaneously. Recently, PET/MRI has been investigated in several cancers with promising results. In this study, we prospectively investigate the role of multiparametric PET/MRI in evaluating the outcome of patients with esophageal cancer treated by neoadjuvant chemoradiotherapy and surgery.

ICD-10 classifications

Carcinoma in situ: OesophagusMalignant neoplasm of oesophagusMalignant neoplasm: Middle third of oesophagusMalignant neoplasm: Overlapping lesion of oesophagusMalignant neoplasm: Upper third of oesophagus

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05855291
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05855291 through Pure Global AI's free database. This phase not specified trial is sponsored by Chang Gung Memorial Hospital and is currently Completed. The study focuses on Esophageal Cancer. Target enrollment is 43 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.